Cell line . | Olaparib IC50 (μM) . | Rucaparib IC50 (μM) . | TalazoparibIC50 (nM) . |
---|---|---|---|
LNCaP | 0.14± 0.03 | 0.47± 0.08 | 0.73± 0.09 |
C4-2B | 1.35 ± 0.23 | 3.01 ± 0.17 | 5.43 ± 1.33 |
PC3 | 4.12 ± 0.82 | 2.60 μM ± 0.23 | 8.45 ± 1.90 |
MDA-PCA-2B | 7.39 ± 1.63 | 1.8 ± 0.33 | 8.61 ± 2.91 |
22RV1 | 10.87 ± 1.89 | 2.48 ± 0.65 | 19.25 ± 4.11 |
Cell line . | Olaparib IC50 (μM) . | Rucaparib IC50 (μM) . | TalazoparibIC50 (nM) . |
---|---|---|---|
LNCaP | 0.14± 0.03 | 0.47± 0.08 | 0.73± 0.09 |
C4-2B | 1.35 ± 0.23 | 3.01 ± 0.17 | 5.43 ± 1.33 |
PC3 | 4.12 ± 0.82 | 2.60 μM ± 0.23 | 8.45 ± 1.90 |
MDA-PCA-2B | 7.39 ± 1.63 | 1.8 ± 0.33 | 8.61 ± 2.91 |
22RV1 | 10.87 ± 1.89 | 2.48 ± 0.65 | 19.25 ± 4.11 |
Cell line . | Olaparib IC50 (μM) . | Rucaparib IC50 (μM) . | TalazoparibIC50 (nM) . |
---|---|---|---|
LNCaP | 0.14± 0.03 | 0.47± 0.08 | 0.73± 0.09 |
C4-2B | 1.35 ± 0.23 | 3.01 ± 0.17 | 5.43 ± 1.33 |
PC3 | 4.12 ± 0.82 | 2.60 μM ± 0.23 | 8.45 ± 1.90 |
MDA-PCA-2B | 7.39 ± 1.63 | 1.8 ± 0.33 | 8.61 ± 2.91 |
22RV1 | 10.87 ± 1.89 | 2.48 ± 0.65 | 19.25 ± 4.11 |
Cell line . | Olaparib IC50 (μM) . | Rucaparib IC50 (μM) . | TalazoparibIC50 (nM) . |
---|---|---|---|
LNCaP | 0.14± 0.03 | 0.47± 0.08 | 0.73± 0.09 |
C4-2B | 1.35 ± 0.23 | 3.01 ± 0.17 | 5.43 ± 1.33 |
PC3 | 4.12 ± 0.82 | 2.60 μM ± 0.23 | 8.45 ± 1.90 |
MDA-PCA-2B | 7.39 ± 1.63 | 1.8 ± 0.33 | 8.61 ± 2.91 |
22RV1 | 10.87 ± 1.89 | 2.48 ± 0.65 | 19.25 ± 4.11 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.